Today, a person's genetic background is considered in everyaspect of clinical medicine, ranging from susceptibility todiseases, pathogenesis, and clinical outcome to diversity inresponses to drug treatment (pharmacogenomics). The new panoramiclook at the human genome has stimulated a massive search forclinically relevant genomic information, including single-nucleotidepolymorphisms (SNPs), which consist of substitutions of onenucleotide for another in a DNA sequence.
Individual genomes are 99.9 percent identical, with only 0.1percent of the genome showing polymorphisms.1,2 About 2 millionor 3 million SNPs have been found in exonic, intronic, regulatory,and intergenic regions. Almost all genes . . . [Full Text of this Article]
This article has been cited by other articles:
Cipollone, F.
(2006). Deoxyribonuclease I: exploring the hidden side of myocardial infarction. Eur Heart J
27: 2031-2033
[Full Text]
Liu, W., Innocenti, F., Ratain, M. J., Kato, N., Wang, Y., Omata, M.
(2005). Linkage Disequilibrium across the UGT1A Locus Should Not Be Ignored in Association Studies of Cancer Susceptibility. Clin. Cancer Res.
11: 1348-1349
[Full Text]
Heckbert, S. R., Hindorff, L. A., Edwards, K. L., Psaty, B. M., Lumley, T., Siscovick, D. S., Tang, Z., Durda, J. P., Kronmal, R. A., Tracy, R. P.
(2003). {beta}2-Adrenergic Receptor Polymorphisms and Risk of Incident Cardiovascular Events in the Elderly. Circulation
107: 2021-2024
[Abstract][Full Text]
Mannucci, P. M., Peyvandi, F., Ardissino, D., Yamada, Y., Yokota, M.
(2003). Risk of Myocardial Infarction and Polymorphisms in Candidate Genes. NEJM
348: 1176-1177
[Full Text]